Interleukin-1α increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the sezary syndrome compared to normal lymphocytes

Journal of Clinical Immunology

Volumn 18, Issue 3, 1998, Pages 223-234

  Salard, Dominique ^a   Kuzel, Timothy M ^a   Samuelson, Ellen ^a   Rosen, Steven ^a   Bakouche, Ouahid ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INSERM   (France)

Author keywords

Cytotoxicity; IL 2 diphtheria toxin fusion protein; Interleukin 1 (IL 1 ); Neoplastic lymphocytes; Sezary syndrome

Indexed keywords

DIPHTHERIA TOXIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG RECEPTOR BINDING; ENDOCYTOSIS; GENE SEQUENCE; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SYNTHESIS INHIBITION; SEZARY SYNDROME;

EID: 0031808379     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020587123523     Document Type: Article

References (37)

1. Kuzel TM, Roenigk HH Jr, Rosen ST: Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis, and therapy. J Clin Oncol 9:1298-1313, 1991
2. 486IL2) in hematologic malignanciers expressing the IL2 receptor. Blood 79:2547-2554, 1992
3. 486IL2: Efficacy iun mycosis fungoides and other non-Hodgkin's lymphomas. Leukemia Lymphoma 11:369-377, 1993
4. Hesketh P, Caguio P, Koh H, Dewey H, Facada A, McCaffrey R, Parker K, Nylen P, Woodworth T: Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 11:1682-1690, 1993
5. 389IL2 is well tolerated at doses inducing response in IL2-receptor expressing lymphomas. Proc Am Soc Hematol Blood 82:137a, 1993
6. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR: Diphtheria toxin receptor binding domain substitution ith interleukin-2: Genetic construction and properties of dipheterial toxin-related interleukin-2 fusion protein. Prot Eng 1:493-498, 1987
7. Woodworth T, Nichols J: recombinant fusion toxins-a new class of targeted biologic therapeutics. In Cancer Treatment and Research: Immunoconjugate Therapy of Hematologic Malignancies. ST Rosen, TM Kuzel (eds), 1993, pp 145-160
8. Robb RJ, Munck A, Smith KA: T-cell growth factor receptors: Quantitation, specificity and biologic relevance. J Exp Med 154: 1455-1474, 1981
9. Sharon M, Kausner RD, Cullen BR, Chizzonite R, Leonard WJ: Novel interleukin-2 receptor subunit detected by cross-linking under high affinity conditions. Science 234:859, 1987
10. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Nakamura M, Sugamura K: Cloning of the gamma chain of the human IL2 receptor. Science 257:379-382, 1992
11. 486IL-2). J Biol Chem 265:11885-11889, 1990
12. Hatakeyama M, Mori H, Doi T, Taniguchi T: A restricted cytoplasmic region of IL-2 receptor β chain is essential for growth signal transduction but not for ligand binding and internalization. Cell 59:837-845, 1989
13. Hemar A, Lieb M, Subtil A, DiSanto JP, Dautry-Varsat A: Endocytosis of the beta chain of interleukin-2 receptor requires neither interleukin-2 nor the gamma chain. Eur J Immunol 24: 1951-1955, 1994
14. Minamoto S, Hatakeyama M, Kono T, Doi T, Ide T, Uede T, Taniguchi T: Characterization of the heterotrimeric complex of human IL-2 receptor alpha.beta chains reconstituted in a mouse fibroblast cell line, L929. J Immunol 145:2177-2182, 1990
15. Waters CA, Schimke PA, Snider CE, Itoh K, Smith KA, Nichols JC, Strom TB, Murphy JR: Interleukin-2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 20:755-791, 1990
16. 389IL-2 in cultutred hematopoietic cells. Cancer Res 56:2590-2595, 1996
17. 389 interleukin-2 receptor binding domain mutations. Cytotoxic probes for studies of ligand-recpetor interactions. J Biol Chem 271:12145-12149, 1996
18. Bacha P, Williams DP, Waters C, William JM, Murphy JR, Strom T: Interleukin-2 receptor targeted cuyploxicity: Interleukin-2 receptor-mediated action of diphtheria IL2-toxin related IL-2 fusion protein. J Exp Med 167:612-622, 1988
19. Kiyokawa T, Williams DP, Snider CE, Strom TB, Murphy JR: Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng 4:463-468, 1991
20. Smith KA: The interleukin-2 receptor. Adv Immunol 42:165-179, 1988
21. Caliguri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J: Functional consequences of interleukin-2 receptor expression on resting human lymphocytes: Identification of a novel natural killer cell subset with high affinity receptor. J Exp Med 171:1509-1526, 1990
22. Waldmann TA: The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727-732, 1986
23. Dinarello CA: Intereleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652, 1991
24. Ruhl S, Schwabe M, Pluznic DH: Interleukin-1 augments the expression of the interleukin-2 receptor alpha chain in interleukin-6 stimulated myeloid cells by a transcriptional and post-transcriptional mechanism. Exp Hematol 20:1208-1215, 1992
25. Plaetinck G, Combe MC. Corthesy P, Sperisen P, Kanamori H, Honjo T, Nabholz M: Control of the IL-2 receptor a chain expression by IL-1, tumor necrosis factor and IL-2. J Immunol 145:3340-3347, 1990
26. Panzer S, Madden M, Matsuki K: Interaction of IL-I β, IL-6, and tumor necrosis factor a in human T-cells activated by murine antigens. J Immunol 93:471-478, 1993
27. Smith IL, Urba JV, Curti BD, Elwood LJ, Steis RG, Junik JE, Sharfman WH, Miller IL, Fenton RG, Conlon KC, Sznol M, Creekmore SP, Wells NF, Ruscetti FW, Keller JR, Hestdal K, Shimizu M, Rossio J, Alvord WG, Oppenheim JJ, Longo DL: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciers. J Clin Oncol 10:1141-1152, 1992
28. Morrey KM, McLachlan JA, Serkin DC, Bakouche O: Activation of human monocytes by the pineal hormone melatonin. J Immunol 153:2671-2680, 1994
29. Mossmann T: Rapid colorimeric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1993
30. Robb RJ, Grecne WC, Risk GM: Low and high affinity cellular receptors for interleukin-2: Implications for the level of Tac antigen. J Exp Med 160:1126-1146, 1984
31. Waldmann TA, Greene WC, Sarin PS, Saxinger C, Blayney DW, Blattner WA, Goldman CK, Bongiovanni K, Sharrow S, Depper JM: Functional and phenolypic comparison of human T-cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human recptor for T-cell growth factor. J Clin Invest 73:1711-1718, 1984
32. Hatakayama M, Tsudo M, Minatomo S, Kono T, Doi T, Miyata T, Miyasaka M, Taniguchi T: Interleukin-2 receptor beta chain gene: Generation of three receptor forms by cloned human alpha and beta chain cDNAs. Science 244:551-556, 1989
33. Furse RK, Malek TR: Selection of internalization-deficient cells by interleukin-2 pseudomonas exoIL-2 toxin chimeric protein: The cytoplasmic domain of ihe interleukin-2 receptor beta chain does not contribute to internalization of interleukin-2. Eur J Immunol 23:3181-3188, 1993
34. Yamaizumi M, Mekatla E, Uchida T, Okada Y: One molecule of diphtheria 1L-2 toxin fragment A introduced into a cell can kill the cell. Cell 15:245-250, 1978
35. Nakamura M, Asao H, Takeshita T, Sugamara K: Interleukin-2 receptor heterodimer complex and intracellular signalling. Semin Immunol 5:309-317, 1993
36. Waldmann TA: The multi-subunit interleukin-2 receptor. Annu Rev Biochem 58:875-911, 1989
37. Weil D. Dautry F: Induction of tumor necrosis factor α and β and Interferon γ mRNA by interleukin 2 in murine lymphocytic cell lines. Oncol Res 3:409-414, 1988